

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

**WORK EXPERIENCE**

---

- 1992-Present                      Private practice, Diseases and Surgery of the Retina and Vitreous  
President, **Associated Retina Consultants, Ltd.**  
1750 E Glendale Avenue  
Phoenix, Arizona 85020
- 2006-2014                        Clinical Instructor, Department of Ophthalmology, University of Arizona
- 2014-Present                      Clinical Assistant Professor in the Department of Ophthalmology, University of Arizona

**EDUCATION**

---

- 1979-1983                        **University of Michigan**, Ann Arbor, Michigan  
*B.S. with High Distinction, Psychology*
- 1983-1987                        **The Johns Hopkins University School of Medicine**, Baltimore, Maryland  
*M.D. with Highest Honors (Alpha Omega Alpha – Top 10% of Graduating Class)*

**POST-GRADUATE TRAINING**

---

- 1987-1989                        **Internship in Internal Medicine**, Evanston Hospital/Northwestern  
*University Affiliated Hospital, Evanston, Illinois*
- 1988-1991                        **Residency in Ophthalmology**, Cullen Eye Institute Baylor College of Medicine  
Houston, Texas
- 1991-1992                        **Fellowship**, The Retina Institute of Maryland, Baltimore, Maryland  
*Vitreoretinal Diseases and Surgery*

**ARIZONA MEDICAL LICENSE #20905**

---

**BOARD CERTIFICATION**

---

- 1992                                **American Board of Ophthalmology**  
October Federation Licensing Examination, June, 1987
- Recertified 2003, 2013            **American Board of Ophthalmology**, Recertified

**AWARDS AND HONORARY SOCIETIES**

---

- 1979-1983                        **University of Michigan**, Dean's Scholar List
- 1980                                **William J. Branstrom Freshman Prize for Academic Achievement**  
*(Top 3 % of Class)*
- 1983                                **Mortar Board Honorary Society Finalist**  
**Golden Key National Honor Society**  
**Psi Chi National Honor Society in Psychology**

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

- 1987                      **Alpha Omega Alpha (AOA) Medical Honor Society**  
Johns Hopkins Chapter
- 1990                      **The Everett L. Goar Research Award in Ophthalmology**  
Baylor Ophthalmology Alumni Association  
Awarded Best Research Paper by a Resident

**MEMBERSHIPS AND ASSOCIATIONS**

---

University of Michigan Alumni Association  
Johns Hopkins University School of Medicine Alumni Association  
Alpha Omega Alpha Medical Honor Society  
American Medical Association  
American Academy of Ophthalmology  
Baylor College of Medicine Alumni Association  
Phoenix Ophthalmological Society  
Arizona Ophthalmological Society  
Associate Director for Retina Services, Maricopa County Medical Center

**ELECTED POSITIONS AND ACTIVITIES**

---

- 1981-1982                Vice-President, Sigma Alpha Mu Fraternity  
Rush Chairman/Community Service Committee
- 1981-1983                University of Michigan Junior Varsity Tennis
- 1983-1985                American Medical Student Association, Representative  
Johns Hopkins Chapter
- 2003-2004                President, Phoenix Ophthalmological Society

**RESEARCH**

---

- 1981                      "Cerebellar Vermis in Schizophrenia", Marceline G. Reyes, M.D., preceptor,  
Department of Neuropathology, Mount Sinai Hospital, Chicago, Illinois.
- 1982                      "Discriminant Validity of the Rational Behavior Inventory Test", Department of  
Psychology, University of Michigan, Ann Arbor, Michigan.
- 1985-1986                "Ophthalmic Manifestations of Leukemia", Andrew P. Schachat, M.D., preceptor, Wilmer  
Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland.
- "The Usefulness of Preoperative Testing in Ophthalmic Patients", Teri A.  
Manalio, M.D., preceptor, Wilmer Eye Institute, Johns Hopkins Hospital,  
Baltimore, Maryland.
- "A Histopathologic Study of Fibrous Xanthoma", W. Richard Green, M.D.,  
preceptor, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland.

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

- RESEARCH [cont'd]** "Hematoporphyrin Derivative Phototherapy in the Treatment of Choroidal Melanoma", Gerard A. Luty, Ph.D., preceptor, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland.
- 1990** "In-vitro Antibiotic Susceptibility of Bacillus Isolates: Implications for Treatment of IV Drug Abuse and Post-traumatic Endophthalmitis", Cullen Eye Institute, Baylor College of Medicine, Houston, Texas.
- 1991** "Efficacy and Retinal Toxicity of Intravitreal Temafloxacin", Cullen Eye Institute, Baylor College of Medicine, Houston, Texas.
- 1991-1992** "Fluorescein Angiography Interpretation of the TGF-Beta 2 Macular Hole Study", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "Scanning Laser Ophthalmoscope Analysis of Macular Holes in Response to TGF-Beta", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "Pseudophakic Retinal Detachment Repair Using Pars Plana Vitrectomy and Liquid Perfluorocarbons", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "Retinal Toxicity of Intravitreal Amiloride in the Rabbit Model", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "TGF-Beta in the Treatment of Subfoveal Neovascular Membranes in Humans", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "Rhegmatogenous Retinal Detachment Repair Using Pars Plana Vitrectomy and TGF-Beta in the Primate Model", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "Intravitreal Penetration of Orally Administered Ciprofloxacin Regimens", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- "Intraoperative Posterior Lenticular Streaking During Pars Plana Vitrectomy", The Retina Center at Saint Joseph Hospital, Baltimore, Maryland.
- 1997** HOE 901/3006 Clinical Study. Carl T. Hayden VAMC.
- 1998** Roche Clinical Drug Study, Valganciclovir (RO 107-9070) (oral prodrug of ganciclovir for treatment of CMV retinitis). Phoenix, Arizona
- 1999** Pharmacia & Upjohn Company Phase III, Double Masked Study of SNET2, Photodynamic Therapy in the Treatment of Subfoveal Choroidal Neovascularization associated with Age-related Macular Degeneration. Phoenix, Arizona
- AMDRT Age-related Macular Degeneration Radiotherapy Trial. Phoenix, Arizona
- 2002** Alcon Research Ltd., An Evaluation of Efficacy and Safety of Posterior Juxtapalpebral Injections of Anecortave acetate 15 mg (0.5 ml of 30mg/ml Anecortave acetate sterile suspension) vs. Visudyne in Patients with Subfoveal Exudative Age-Related Macular

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

**RESEARCH [cont'd]**

Degeneration (AMD) Eligible for Initial Treatment with Photodynamic Therapy (PDT) Using Visudyne. Phoenix, Arizona

**2003**

Genentech Inc., FVF2428g(FOCUS): A Phase I/II Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin (Visudyne™) Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

Genentech, Inc. FVF2598g (MARINA): A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular. Phoenix, Arizona

**2004**

Alcon C-02-60: An Evaluation of the Efficacy and Safety of Posterior Juxtasclear Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Patients (Enrolled in Study "A" or Study "B") at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age-Related Macular Degeneration (AMD). Phoenix, Arizona

Genentech, Inc. FVF3192g (PIER): A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) with or without Classic CNV Secondary to Age-Related Macular Degeneration. Phoenix, Arizona

**2005**

Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc. EOP1013:A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injection of 0.3, 0.03, or 0.003 mg Pegaptanib Sodium (Macugen®), Given as Often as Every 6 Weeks for 3 Years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) involving the Center of the Macula. Phoenix, Arizona

Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc EOP1012: A Phase 3B/4, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Macugen® Given Every 6 Weeks for Up to 102 Weeks, Plus Sham Photodynamic Therapy (PDT), to Macugen® plus PDT with Visudyne® in Subjects with Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Phoenix, Arizona

Alcon C-04-59: Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15mg Administered Every 6 Months Versus Anecortave Acetate 30mg Administered Every 6 Months in Patients with Exudative Age-Related Macular Degeneration (AMD). Phoenix, Arizona

Genentech, Inc. FVF3426g (HORIZON): An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of A Genetech-Sponsored Ranibizumab Study. Phoenix, Arizona

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

**RESEARCH [cont'd]**

Genentech, Inc. FVF3689g (SAILOR): A Phase IIIb, Single-Masked, Multicenter, Randomized Study Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Phoenix, AZ

**2006**

Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc EOP1014: An Exploratory Randomized, Double-Masked, Multi-Center, Multi-Dose, Comparative Trial, In Parallel Groups, To Explore the Safety and Efficacy of Three Different Doses of Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 102 Weeks, In Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD). Phoenix, Arizona

Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc EOP1023: A Phase IV, Open-Label, Multi-Center Trial of Maintenance Intravitreal Injections of Macugen® (Pegaptanib Sodium) Given Every 6 Weeks For 48 Weeks In Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With A Different Modality Resulting In Maculopathy Improvement. Phoenix, Arizona

Allergan, Inc. Protocol 206207-009: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion. Phoenix, Arizona

Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-0508 Clinical Evaluation of Anti-angiogenesis in the Retina Intravitreal Trial AMD Phase 2 (CLEAR-IT AMD-2): A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

**2007**

Eli Lilly and Company. Protocol B7A-MC-MBCU: The Effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography. Principal Investigator. Phoenix, Arizona

Regeneron Pharmaceuticals, Inc , Protocol VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

Regeneron Pharmaceuticals, Inc , Protocol VGFT-OD-0702: An Open-Label, Long-Term, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

QLT Inc. Protocol BPD OCR 022: A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne®-Lucentis® Combination Therapies and Lucentis Monotherapy in Subjects with CNV Secondary to AMD. Phoenix, Arizona

Genentech, Inc. FVF4165g (BRAVO): A Phase III, Multicenter, Randomized, Sham

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

**RESEARCH [cont'd]**

Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion. Phoenix, Arizona

Genentech, Inc. FVF4166g (CRUISE): A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion. Phoenix, Arizona

Genentech, Inc. FVF4168g (RIDE): A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Phoenix, Arizona

**2008**

Thrombogenics, Inc. Protocol TG-MV-006: A Randomized, Placebo Controlled, Double-Masked, Multicenter Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. Phoenix, Arizona

Opko Health, Inc. A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Monotherapy Every 4 Weeks in Patients with Exudative Age-related Macular Degeneration (AMD). Phoenix, Arizona

**2009**

Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-0819: A Randomized, Double-Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administrations of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Phoenix, Arizona

Genentech, Inc. FVF4579g (HARBOR): A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study Of The Efficacy And Safety Of 0.5 mg And 2.0 mg Ranibizumab Administered Monthly Or On An As-Needed Bases (PRN) In Patients With Subfoveal Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

**2010**

GlaxoSmithKline MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

**2011**

Alcon Protocol C-10-083: Safety and Efficacy of ESBA1008 versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration. Phoenix, Arizona  
Allergan, Inc. GMA-OZU-09-011: A Retrospective Data Collection Study in Patients Receiving Two or More Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Retinal Vein Occlusion. Phoenix, Arizona

Genentech FVF4967g (SHORE): A Multicenter Randomized Study for Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion. Phoenix, Arizona

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

**RESEARCH [cont'd]**

GlaxoSmithKline BAM114341: A Phase 2, Multi-centre, Randomized, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).  
Phoenix, Arizona

LPATH LT1009-Oph-003 (Nexus): A Phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSONEP™ (Sonepcizumab [LT1009]) as Either Monotherapy or Adjunctive Therapy to Lucentis® or Avastin® Versus Lucentis® or Avastin® Alone in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Phoenix, Arizona

Regeneron VGFT-OD-0910: An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

Regeneron VGFT-OD-1009: A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Phoenix, Arizona

**SCIENTIFIC PRESENTATIONS**

---

- 1986** "Ophthalmic Manifestations of Leukemia", Alan J. Gordon, B.S., Andrew P. Schachat, M.D., Philip J. Burke, M.D., Michael Graham, Jan A. Markowitz, The Wilmer Resident's Association 45th Annual Meeting, April 17, 1986, Baltimore, Maryland.
- "Simple Criteria for Focusing Use of Preoperative Serum Chemistries in Ophthalmic Patients", Teri A. Manalio, M.D., Alan J. Gordon, B.S., Andrew P. Schachat, M.D., The Society for Research and Education in Primary Care Internal Medicine 10th Anniversary National Meeting, April 30, 1986, San Diego, California.
- 1990** "In-vitro Antibiotic Susceptibility of Bacillus Isolates: Implications for Treatment of IV Drug Abuse and Post-traumatic Endophthalmitis", Alan J. Gordon, M.D., Michael S. Osato, Ph.D., David Parke II, M.D., The 27th Annual Meeting Baylor Ophthalmology Alumni Association, June 9, 1990, Houston, Texas.
- 1991** "In-vitro Antibiotic Susceptibility of Ocular Bacillus Isolates to Combination Drug Therapy", Alan J. Gordon, M.D., Michael S. Osato, Ph.D., David W. Parke II, M.D., The Association for Research in Vision and Ophthalmology, May 2, 1991, Sarasota, Florida.
- "Retinal Toxicity of Intravitreal Temafloxacin", Alan J. Gordon, M.D., Melinda Rainey, Hardeep S. Dhindsa, M.D., Michael S. Osato, Ph.D., David W. Parke II, M.D., The 28th Annual Meeting Baylor Ophthalmology Alumni Association, June 6, 1991, Houston, Texas.
- "Retinal Toxicity of Intravitreal Temafloxacin", Alan J. Gordon, M.D., Melinda Rainey, Hardeep S. Dhindsa, M.D., Michael S. Osato, Ph.D., David W. Parke II, M.D., Annual Meeting American Academy of Ophthalmology - O.M.T.G., October 12, 1991, Anaheim, California.

**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

- 2007** "Retina 2007 Symposium: Understanding New Developments and Treatment Methods for Vitreoretinal Diseases". Presented by Associated Retina Consultants, Hilton Squaw Peak, March 3, 2007, Phoenix, Arizona.
- 2008** "Retina 2008 Symposium: Understanding New Developments and Treatment Methods for Vitreoretinal Diseases". Presented by Associated Retina Consultants, Hilton Squaw Peak, November 1st, 2008, Phoenix, Arizona.
- 2012** "Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities". Kiran Turaka, M.D., J. Shepard Bryan, M.D., H. Mark Kwong Jr., M.D., Stephen A.M. De Souza, M.D., Alan J. Gordon, M.D., Rahul K. Reddy, M.D., Matthew C. Ziemianski, M.D., Clive H. Sell, M.D. Poster presentation (#3074) at 54th American Society for Therapeutic Radiation Oncology (ASTRO) 2012 Annual Meeting, Boston, MA October 28-31, 2012.
- "Vitreoretinal Lymphoma and Intravitreal Chemotherapy: Ocular and Systemic Outcomes". Kiran Turaka, M.D., Alan J. Gordon, M.D., J. Shepard Bryan, M.D., H. Mark Kwong, Jr., M.D., Stephen A.M. De Souza, M.D., Rahul K. Reddy, M.D., Matthew C. Ziemianski, M.D., Clive H. Sell, M.D. Poster presentation at the Pan Pacific Lymphoma Conference (PPLC), July 17-20, 2012, Island of Maui, Hawaii. Received the Travel grant award for the poster presentation.
- 2013** "Short Term Effect of Intravitreal Aflibercept Injection In IntraOcular Pressure". Presented by Alan J. Gordon, M.D., Stephen A.M. De Souza, M.D., H. Mark Kwong, Jr., M.D. Rahul K. Reddy, M.D., Clive H. Sell, M.D., Belinda L. Shirkey, M.D., J. Shepard Bryan, M.D., Matthew C. Ziemianski, M.D., Kasra A. Rezaei, M.D., Carmel Moazez, at 2013 ARVO Scientific Meeting, Seattle, Washington.
- "Optical coherence tomographic findings in Wet Age Related Macular Degeneration after Intravitreal Aflibercept Injection". Presented by Alan J. Gordon, M.D., Stephen A.M. De Souza, M.D., H. Mark Kwong, Jr., M.D. Rahul K. Reddy, M.D., Clive H. Sell, M.D., Belinda L. Shirkey, M.D., J. Shepard Bryan, M.D., Matthew C. Ziemianski, M.D., Kasra A. Rezaei, M.D., Carmel Moazez, at 2013 ARVO Scientific Meeting, Seattle, Washington.
- "Prophylactic Treatments for Retinal Tears/Detachment in Stickler Syndrome: Single Institution Experience". Presented by Alan J. Gordon, M.D., Clive H. Sell, M.D., J. Shepard Bryan, M.D., Kiran Turaka, M.D., Oral Paper presentation at ARVO 2013 annual meeting, Seattle WA May 5-9, 2013 (#4958).



**CURRICULUM VITAE**  
**ALAN J. GORDON, M.D.**

**PUBLICATIONS**

---

1. Reyes, M.G.; **Gordon A.J.**: "Cerebellar Vermis in Schizophrenia", *Lancet*. 1981; 2:700-701.
2. Thyer, B.A.; **Gordon A.J.**; Miller E.; Papsdorf, J.D.: "Discriminant Validity of the Rational Behavior Inventory With Respect to Social Desirability", *Psychological Reports*. 1982; 51:370.
3. **Gordon, A.J.**; Patrinely, J.R.; Knupp, J.A.; Font, R.L.: "Complex Choristoma of the Eyelid Containing Ectopic Cilia and Lacrimal Gland", *Ophthalmology*. 1991; 98(10):1547-50.
4. Lansing, M.D.; Glaser, B.M.; Liss, H; Hanham, A; Thompson, J.T.; Sjaarda, R.N.; Gordon, A.J.: "The Effect of Pars Plana Vitrectomy and Transforming Growth Factor - Beta 2 Without Epiretinal Membrane Peeling on Full-Thickness Macular Holes", *Ophthalmology (United States)*. June 1993; 100(6):868-71; discussion 871-72.
5. Thompson, J.T.; Hiner, C.J.; Glaser, B.M.; **Gordon, A.J.**; Murphy, R.P.; Sjaarda, R.N.: "Fluorescein Angiographic Characteristics of Macular Holes Before and After Vitrectomy with Transforming Growth Factor Beta-2", *American Journal of Ophthalmology*. March 1994; 117(3):291-301.
6. Lansing, M.D.; Glaser, B.M.; Liss, H; Hanham, A; Thompson, J.T.; Sjaarda, R.N.; **Gordon, A.J.**: "The Effect of Pars Plana Vitrectomy and Transforming Growth Factor - Beta 2 Without Epiretinal Membrane Peeling on Full-Thickness Macular Holes", *Comment Ophthalmology*. June 1994; 101(6):972-73.
7. Turaka K, Bryan JS, **Gordon AJ**, Reddy R, Kwong HM Jr, Sell CH. Laser pointer induced macular damage: case report and mini review. *Int Ophthalmol* 2012 Jun; 32(3):293-7. Epub 2012 Apr 1.
8. Turaka K, Bryan JS, **Gordon AJ**, Kwong HM Jr, Reddy R, Tsipursky M, Sell CH. Clinical and image-guided chorioretinal findings in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. *J Pediatr Endocrinol Metab* 2012; 25(5-6):565-7.
9. K. Turaka, J. S. Bryan, H. M. Kwong Jr., S. De Souza, **A. J. Gordon**, R. Reddy, M. C. Ziemianski, C. H. Sell. Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities. *Int J Rad Oncol Biol Phys* 2012; 1 Nov (3S) 84:S621-22.
10. Turaka K, Bryan JS, De Souza S, **Gordon AJ**, Kwong HM Jr, Ziemianski MC, Reddy R, Sell CH. Vitreoretinal Lymphoma: Changing Trends in Diagnosis and Local Treatment Modalities at a Single Institution. *Clin Lymphoma Myeloma Leuk*. 2012 Dec;12(6):412-7 [Epub 2012 Sep 18].
11. Turaka K, **Gordon AJ**, Patel S, Bryan JS, Kwong HM Jr, Dugel PU, Arogyasami RM. Diagnostic and therapeutic challenges. *Retina*. 2013 Mar;33(3):661-5.
12. Tsipursky MS, Heller MA, De Souza SA, **Gordon AJ**, Bryan JS, Ziemianski MC, Sell CH.: Comparative evaluation of no dye assistance, indocyanine green and triamcinolone acetonide for internal limiting membrane peeling during macular hole surgery, *Retina*. 2013 Jun;33(6):1123-31. doi: 10.1097/IAE.0b013e31827b63ce.